CANDIDATE:

Bridge to Candidacy

for patients who need time to manage factors that make them ineligible for transplant.

Clinical scenario

- Unexplained weight gain, fluid retention, shortness of breath, winded after only walking a few feet.
- EF: 15%
- Because it was during the pandemic, Rick wasn't able to do many in-person appointments (only telehealth)

LVAD Implant

Device: HeartMate 3 LVAD

LVAD Implant Date: August 5, 2022

Age at Implant: 38

Procedure: Full-Sternotomy

Post-implant: Transplanted at 41 years old and 190lbs.

Rick

- **41 yr old man**
- **Bio/Activity**: Diagnosed with congestive heart failure and dilated cardiomyopathy, Rick faced a difficult prognosis. Rick was referred to an advanced heart failure clinic. At age 38, weighing 344 pounds, he received his LVAD implantation. Determined to earn a chance at heart transplant, Rick committed to lifestyle changes, losing more than 150 pounds with daily walks, gym sessions, and yardwork. Listed for transplant at 210 pounds in May 2023, he reached 190 pounds by June 2025 and successfully received a new heart at 41.

Medical History

Diagnosis: CHF; Dilated Cardiomyopathy

Medications: Entresto 24/26; Farxiga 10mg; Warfarin 7.5mg; Metoprolol 12.5mg

Other Procedures: Pacemaker/defibrillator

HF Classification: Data unavailable.

Living with LVAD

"The doctors and surgeons did their part. After the surgery, it was my turn to do mine. I put in the work to get healthy enough for transplant. I wouldn't have gotten here if it wasn't for the LVAD."

Abbott
6101 Stoneridge Dr., Pleasanton, CA 94588 USA,
Tel: 1 925 847 8600

cardiovascular.abbott/lvad-patient-case-study-profiles

These testimonials relate an account of an individual's response to the treatment. The patient's account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.

Rx Only
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

HeartMate 3™ LVAS Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

HeartMate 3™ LVAS Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3™ LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third party trademark, which is property of its respective owner.
© 2026 Abbott. All Rights Reserved.
MAT-2515405 v2.0 | Item approved for U.S. use only.